Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Hôpital Erasme, Brussels

UZ Brussels, Brussels

UCL Saint-Luc, Brussels

Frederiksbergs Hospital, Frederiksberg

UZ Antwerpen, Edegem

Herlev University Hospital, Herlev

UZ Leuven, Leuven

CHU de Liège, Liège

Odense Universitets hospital, Odense

AOU San Luigi Gonzaga, Torino

Hôpital Nord, Marseille

Hospital Juan Canalejo, A Coruña

IRCCS Fondazione S. Raffaele del Monte Tabor, Milan

Hospital General Universitario, Madrid

Hospital 12 de Octubre, Madrid

Hospital Infanta Sofía, Madrid

CHU Toulouse, Toulouse

Hôpital Pellegrin, Bordeaux

Clinique Beau Soleil, Montpellier

CHU Michalon, Grenoble

CHU Nantes, Nantes

Instituto de Oncología, Valencia

Hospital de Basurto, Bilbao

Private practice, Nancy

Chru Lille, Lille

Hôpital Henry Gabrielle, Saint-Genis-Laval

Oncology Institute, Bucharest

Hôpital Val de Grâce, Paris

Institut Mutualiste Monsouris, Paris

Clinique Rhône Durance, Avignon

Hôpital Foch, Suresnes

CHU Henri Mondor, Créteil

Fredericia Sygehus, Fredericia

University Hospital, Klaipėda

Ziekenhuis Amstelland, Amstelveen

Antonius Ziekenhuis, Sneek

Medical Center, Arad

Sc E-Uro Srl, Cluj-Napoca

Oncomed, Timișoara

Bristol Royal Infirmary, Bristol

CHU Pasteur, Nice

P.Stradins Clinical University Hospital, Riga

Center of Oncology, Riga

Medical University Clinics, Kaunas

University Oncological Institute, Vilnius

Academisch Medisch Centrum, Amsterdam

Diaconessenhuis, Leiden

Hospital Valle Hebrón, Barcelona

Hospital Clinic, Barcelona

Addenbrookes Hospital, Cambridge

University Hospital Wales, Cardiff

University Hospital Coventry, Coventry

Derby City Hosptial, Derby

Royal Devon and Exeter Hospital, Exeter

Falkirk & District Royal Infirmary, Falkirk

Leicester General Hospital, Leicester

Freeman Hospital, Newcastle upon Tyne

Nottingham City Hospital, Nottingham

Lister Hospital, Stevenage